Evidence map›Paper›PMID 30472178›Full record

ArticleThe Lancet. Infectious diseases2019

The potential effect of improved provision of rabies post-exposure prophylaxis in Gavi-eligible countries: a modelling study.

WHO Rabies Modelling Consortium

Open access · hybridAbstract read
In one paragraph

Article in The Lancet. Infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 129 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Rabies elimination in the WHO African Region.Bulletin of the World Health Organization · 2025
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 18 institutions in 13 countries.

WHO Rabies Modelling Consortium
Swiss Tropical and Public Health Institute · CHUniversity of Glasgow · GBDépartement Santé Animale · FRInstitut Pasteur de Madagascar · MGPrinceton University · USUniversity of Cambridge · GBWorld Health Organization - Pakistan · PKAssociation Sahélienne de Recherche Appliquée pour le Développement Durable · TDCentre de Support en Santé InternationaleGhent University · BEGlobal Alliance for Rabies Control · USKansas State University · USMali-Folkecenter · MLMinistry of Public Health · MGNational Institute Of Hygiene And Epidemiology · VNSwiss Centre for Scientific Research · CIUniversidade Federal de Minas Gerais · BRWashington State University · US

Funding

Wellcome Trust 110330/Z/15/ZWellcome Trust 207569/Z/17/Z
6 · The paper itself

Abstract

backgroundTens of thousands of people die from dog-mediated rabies annually. Deaths can be prevented through post-exposure prophylaxis for people who have been bitten, and the disease eliminated through dog vaccination. Current post-exposure prophylaxis use saves many lives, but availability remains poor in many rabies-endemic countries due to high costs, poor access, and supply.

methodsWe developed epidemiological and economic models to investigate the effect of an investment in post-exposure prophylaxis by Gavi, the Vaccine Alliance. We modelled post-exposure prophylaxis use according to the status quo, with improved access using WHO-recommended intradermal vaccination, with and without rabies immunoglobulin, and with and without dog vaccination. We took the health provider perspective, including only direct costs.

findingsWe predict more than 1 million deaths will occur in the 67 rabies-endemic countries considered from 2020 to 2035, under the status quo. Current post-exposure prophylaxis use prevents approximately 56 000 deaths annually. Expanded access to, and free provision of, post-exposure prophylaxis would prevent an additional 489 000 deaths between 2020 and 2035. Under this switch to efficient intradermal post-exposure prophylaxis regimens, total projected vaccine needs remain similar (about 73 million vials) yet 17·4 million more people are vaccinated, making this an extremely cost-effective method, with costs of US$635 per death averted and $33 per disability-adjusted life-years averted. Scaling up dog vaccination programmes could eliminate dog-mediated rabies over this time period; improved post-exposure prophylaxis access remains cost-effective under this scenario, especially in combination with patient risk assessments to reduce unnecessary post-exposure prophylaxis use.

interpretationInvesting in post-exposure vaccines would be an extremely cost-effective intervention that could substantially reduce disease burden and catalyse dog vaccination efforts to eliminate dog-mediated rabies.

fundingWorld Health Organization.

Indexed as

AnimalsBites and StingsChild, PreschoolCost-Benefit AnalysisDog DiseasesDogsEndemic DiseasesFemaleHumansImmunoglobulinsIncidenceMaleModels, EconomicPost-Exposure ProphylaxisQuality-Adjusted Life YearsRabiesImmunoglobulinsRabies Vaccines

Identifiers

PMID30472178
PMCPMC6300480
OpenAlexW2901306671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.